Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel anti-epidermal growth factor receptor antibody, preparation method and application thereof

An antibody, a new technology, applied in the direction of anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antibody, anti-tumor drug, etc.

Inactive Publication Date: 2015-09-16
TAIZHOU MABTECH PHARM CO LTD
View PDF4 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, antibodies that recognize tumor-specific epitopes of EGFR have the potential to eliminate potentially associated side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel anti-epidermal growth factor receptor antibody, preparation method and application thereof
  • Novel anti-epidermal growth factor receptor antibody, preparation method and application thereof
  • Novel anti-epidermal growth factor receptor antibody, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: Construction of Pan

[0054] Use genetic engineering technology to synthesize the gene sequence of SEQ ID NO: 5 (which expresses the amino acid sequence described in SEQ ID NO: 6), connect it to the expression vector, and transfect it into the host cell CHO, screen for high-expression clones, and carry out mass culture, Expression, separation and purification to obtain the antibody Pan.

[0055] The molecular weight of Pan was determined by polyacrylamide gel electrophoresis (SDS-PAGE) ( figure 1 ). Under non-reducing conditions, a band of Pan was observed at about 200kD.

[0056] And both SDS-PAGE and size-exclusion chromatography (SEC) showed that its molecular size was larger than that of panitumumab before modification. As previously reported, IgG2 panitumumab has two bands of similar molecular size, suggesting that it may be composed of structural isomers. Under reducing conditions, both Pan and panitumumab produced heavy and light chains of approxi...

Embodiment 2

[0057] Example 2: Construction of Pan-P and digestion in vitro

[0058] We used the previously described probody technology to develop Pan-P with enzymatic cleavage activity on the basis of Pan. as in figure 2 The indicated peptides were fused to the light chain of Pan as described in . Its sequence composition is as follows: blocking peptide (IYPPLLRTSQAM), substrate peptide (LSGRSDNH) and serine-glycine linking peptide (GSSGGSGGSGGSG). It has been previously identified that our chosen blocking peptide specifically binds panitumumab but not cetuximab. Urokinase-type plasminogen activator (uPA) is a protease highly expressed in many tumors. In the development of prodrugs (Prodrugs) in recent years, it has been widely used to convert the inactive state of prodrugs into an active state at the tumor site. Therefore, we linked the cleavage site specifically recognized by uPA (LSGRDNH) to the blocking peptide via a serine-glycine linker peptide. To determine whether Pan-P has...

experiment example 1

[0060] Experimental example 1: Activity comparison of Pan

[0061] Competition binding assay to determine the relative binding activities of Pan and Pani. The experimental process is as follows: EGFR-Fc (1 μg / mL) dissolved in PBS (PH=6.84) was coated on a 96-well microplate (Nunc), and the PBS containing 10% skimmed milk powder was used for 1 hour closed. Next, biotin-labeled panitumumab F(ab')2 (1:200) and unlabeled panitumumab or Pan diluted in PBS were mixed and incubated at 37°C for 60 minutes. Then, streptavidin-conjugated HRP (1:1000) was added and incubated at 37 °C for 30 min. The detection method is the same as the EGFR binding ELISA (enzyme-linked immunosorbent assay) test. Curves were fitted using a four-parameter model of the S-curve. see results Figure 5 , the results showed that Pan and Pani had similar relative binding activities, with average EC50 values ​​of 1.849 μg / ml and 2.112 μg / ml, respectively.

[0062] The growth inhibitory effect of Pan on A431...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel anti-epidermal growth factor receptor EGFR antibody, a preparation method and application thereof. The novel whole human source anti-EGFR monoclonal antibody Pan-P provided by the invention is IgG1 type antibody, and has ADCC effect. Also, the antigen-binding site of the antibody provided by the invention contains a section of blocking peptide with tumor-specific protease cleavage site. The antibody is an enzyme-mediated specific binding antibody, has specific binding effect to tumors, and can reduce skin toxicity caused by general anti-EGFR antibodies.

Description

technical field [0001] The invention belongs to the field of biotechnology, and more specifically, the invention discloses a novel fully human epidermal growth factor receptor EGFR monoclonal antibody, its preparation method and its application in the preparation of antitumor drugs. Background technique [0002] Cancer is the second leading cause of death in humans after heart disease, and major advances have been made in new treatments for this deadly disease. Proliferation of normal cells is controlled by activation of their growth factor receptors, such as growth factor receptor tyrosine kinases, by their respective ligands. Cancer cells also proliferate under the activation of growth factor receptors, but lose the tight control of normal proliferation. This loss of control can be caused by many factors, such as overexpression of growth factors or overexpression of growth factor receptors, and spontaneous activation of biochemical pathways regulated by growth factors. R...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28A61K39/395A61P35/00
Inventor 钱卫珠
Owner TAIZHOU MABTECH PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com